15/10/02说明:此前论坛服务器频繁出错,现已更换服务器。今后论坛继续数据库备份,不备份上传附件。

肝胆相照论坛

 

 

肝胆相照论坛 论坛 学术讨论& HBV English APASL2013 潜在的新的治疗目标的病毒性肝炎 陈培哲 ...
查看: 572|回复: 1
go

APASL2013 潜在的新的治疗目标的病毒性肝炎 陈培哲 肝炎研 [复制链接]

Rank: 8Rank: 8

现金
62111 元 
精华
26 
帖子
30441 
注册时间
2009-10-5 
最后登录
2022-12-28 

才高八斗

1
发表于 2013-5-31 10:18 |只看该作者 |倒序浏览 |打印
Abstract
     
Potential New Treatment Target for Viral Hepatitis   
     
Pei-Jer Chen
Hepatitis Reseach Center, National Taiwan University College of Medicine and National Taiwan University Hospital, Taipei, Taiwan R.O.C.

Currentl treamtments for chronic hepatitis B have improved the clinical outcomes of CHB patients. anti-viral Nucs satisfactorily suppress viral replication and prevent the subsequent new rounds of HBV infection in the liver. Interferon augments the host immune responses and occaionally achieves durable viral control or even eradication. However, the likelyhood of current therapies is still deemed low in removing HBV cccDNA or in clearing HBsAg. New therapies targets to viral or host molecules other than viral polymerase are actively explored. Peptides or antibodies effectively preventing HBV infection have been developed and even in early phase clinical trials. Small molecules in disrupting HBV capsid formation also showed some promising progress. New cytokines or small molecules controlling or degrading cccDNA are actively explored. Finally, the potent immuno-enhancers, such as TLR 4/7/9 agonists, have domenstrated signficant anti-HBV acitivities in the relevant animal models. These new progresses will pave the way for the next generation anti-HBV therapies aiming to curative therapies.


Assigned speakers:
Dr. Pei-Jer Chen, National Taiwan University College of Medicine , Taipei , Taiwan R.O.C.

Assigned in sessions:
09.06.2013, 10:30-12:00, Clinical Tracks (CT), CT 3-2, Novel Treatments and Emerging Strategies for Chronic Hepatitis B, Hall 2

Rank: 8Rank: 8

现金
62111 元 
精华
26 
帖子
30441 
注册时间
2009-10-5 
最后登录
2022-12-28 

才高八斗

2
发表于 2013-5-31 10:19 |只看该作者
陈培哲
肝炎研制中心,国立台湾大学医学院和台大医院,台北,中华民国

慢性乙型肝炎Currentl treamtments改善慢性乙型肝炎患者的临床结果。抗病毒Nucs的满意地抑制病毒的复制,防止后续的新一轮感染HBV在肝。干扰素增强宿主的免疫反应和occaionally达到耐用病毒的控制,甚至消灭。然而,目前的治疗方法的情形产生仍被视为低在消除HBV cccDNA的清除乙肝表面抗原。病毒或宿主分子病毒聚合酶以外的新的治疗目标是积极的探索。有效地预防HBV感染的肽或抗体已经开发并即使在早期临床试验中。小分子干扰乙肝病毒衣壳的形成,也表现出一些令人鼓舞的进展。积极探索新的细胞因子或小分子控股或有辱人格的cccDNA的。最后,强效的免疫增强剂,如4/7/9 TLR激动剂,抗HBV domenstrated signficant活动通过在有关的动物模型。这些新的进展铺平了道路,为下一代抗HBV治疗旨在根治疗法。
‹ 上一主题|下一主题
你需要登录后才可以回帖 登录 | 注册

肝胆相照论坛

GMT+8, 2024-5-13 04:34 , Processed in 0.014424 second(s), 11 queries , Gzip On.

Powered by Discuz! X1.5

© 2001-2010 Comsenz Inc.